Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotic Recipe For High Prices: Outcomes Data, Targeted Use

Executive Summary

Drug developers must show value, such as lower death rates, to justify high prices for antibiotics to treat drug resistant organisms, payers note during conference on the Limited Population Antibacterial Drug approval pathway.


Related Content

Antibiotic Incentive Legislation: Can Reimbursement Horn In?
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts